Human Papillomavirus (HPV) Vaccination and the Impact of Vaccine Implementation in Kenya: Progress, Challenges, and Future Directions

Maru Kiplimo Adams; Lelei Walter; Zefaniah Katuah; Njagi Esther; Amy Ogot; Rispah Torrorey; Simeon Mining

doi:doi:10.11648/j.frontiers.20260603.14

Review Article |

| Peer-Reviewed

Human Papillomavirus (HPV) Vaccination and the Impact of Vaccine Implementation in Kenya: Progress, Challenges, and Future Directions

Maru Kiplimo Adams^*

, Lelei Walter

, Zefaniah Katuah, Njagi Esther

, Amy Ogot, Rispah Torrorey, Simeon Mining

Published in Frontiers (Volume 6, Issue 3)

Received: 3 September 2026 Accepted: 17 September 2026 Published: 29 September 2026

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Human papillomavirus (HPV) is the primary etiological agent of cervical cancer, a disease that remains a major cause of cancer-related morbidity and mortality among women in Kenya despite the availability of highly effective prophylactic vaccines. This review examines the current evidence on HPV virology, vaccine immunology, global vaccine effectiveness, and the implementation of HPV vaccination in Kenya following its introduction into the national immunization program in 2019. It also evaluates progress in vaccine delivery, coverage trends, and the adoption of the single-dose vaccination schedule, while highlighting persistent challenges including vaccine hesitancy, inequitable access, health system constraints, and socioeconomic barriers. Available evidence indicates that HPV vaccination has strengthened cervical cancer prevention efforts and has the potential to substantially reduce the future burden of HPV-related disease. However, vaccine coverage remains below the World Health Organization target for cervical cancer elimination, limiting the full public health impact of the program. Key research priorities include evaluating long-term vaccine effectiveness, monitoring HPV genotype dynamics, assessing vaccine performance among people living with HIV, and strengthening the integration of HPV vaccination with cervical cancer screening programs. Achieving equitable vaccine access, enhancing surveillance systems, improving community engagement, and ensuring sustainable financing will be essential to maximizing the benefits of HPV vaccination and accelerating progress toward the elimination of cervical cancer in Kenya.

Published in	Frontiers (Volume 6, Issue 3)
DOI	10.11648/j.frontiers.20260603.14
Page(s)	107-120
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2026. Published by Science Publishing Group

Keywords

Human Papillomavirus, Cervical Cancer Prevention, HPV Vaccination, Vaccine Uptake, Kenya

References

[1]	K. Gopalkrishnan and R. Karim, “Addressing Global Disparities in Cervical Cancer Burden: A Narrative Review of Emerging Strategies,” Dec. 01, 2025, Springer. https://doi.org/10.1007/s11904-025-00727-2
[2]	V. Mwenda et al., “Cervical cancer programme, Kenya, 2011–2020: lessons to guide elimination as a public health problem,” Ecancermedicalscience, vol. 16, 2022, https://doi.org/10.3332/ECANCER.2022.1442
[3]	WHO, “Kenya launches national cervical cancer elimination action plan 2026–2030 \| WHO \| Regional Office for Africa.” Accessed: Jul. 18, 2026. [Online]. Available: https://www.afro.who.int/countries/kenya/news/kenya-launches-national-cervical-cancer-elimination-action-plan-2026-2030
[4]	S. Basoya and A. Anjankar, “Cervical Cancer: Early Detection and Prevention in Reproductive Age Group,” Cureus, Nov. 2022, https://doi.org/10.7759/cureus.31312
[5]	A. Terepka, A. Pryczynicz, and J. Reszeć-Giełażyn, “Analysis of cervical cancer screening attendance before, during, and after the COVID-19 pandemic: six-year laboratory experience,” Medical Studies, 2026, https://doi.org/10.5114/ms.2026.162418
[6]	M. Arbyn, L. Xu, C. Simoens, and P. P. L. Martin-Hirsch, “Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors,” May 09, 2018, John Wiley and Sons Ltd. https://doi.org/10.1002/14651858.CD009069.pub3
[7]	Global strategy to accelerate the elimination of cervical cancer as a public health problem. World Health Organization, 2020.
[8]	J. Doorbar, N. Egawa, H. Griffin, C. Kranjec, and I. Murakami, “Human papillomavirus molecular biology and disease association,” Mar. 01, 2015, John Wiley and Sons Ltd. https://doi.org/10.1002/rmv.1822
[9]	D. A. Haręża, J. R. Wilczyński, and E. Paradowska, “Human Papillomaviruses as Infectious Agents in Gynecological Cancers―Oncogenic Properties of Viral Proteins,” Feb. 01, 2022, MDPI. https://doi.org/10.3390/ijms23031818
[10]	A. A. McBride, “Human papillomaviruses: diversity, infection and host interactions,” Nature Reviews Microbiology 2021 20:2, vol. 20, no. 2, pp. 95–108, Sep. 2021, https://doi.org/10.1038/s41579-021-00617-5
[11]	“Cervical cancer.” Accessed: Jul. 18, 2026. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
[12]	“Human papillomavirus and cancer.” Accessed: Sep. 15, 2026. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/human-papilloma-virus-and-cancer
[13]	“Human Papillomavirus (HPV) Infection - Human Papillomaviruses - NCBI Bookshelf.” Accessed: Sep. 15, 2026. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK321770/
[14]	J. Doorbar et al., “The biology and life-cycle of human papillomaviruses,” 2012, Elsevier Ltd. https://doi.org/10.1016/j.vaccine.2012.06.083
[15]	M. A. Stanley, “Epithelial cell responses to infection with human papillomavirus,” Apr. 2012. https://doi.org/10.1128/CMR.05028-11
[16]	M. Schiffman et al., “Carcinogenic human papillomavirus infection,” Nat. Rev. Dis. Primers, vol. 2, Dec. 2016, https://doi.org/10.1038/nrdp.2016.86
[17]	E. J. Crosbie, M. H. Einstein, S. Franceschi, and H. C. Kitchener, “Human papillomavirus and cervical cancer,” 2013, Elsevier B.V. https://doi.org/10.1016/S0140-6736(13)60022-7
[18]	C. A. Moody and L. A. Laimins, “Papanicolau smear Human papillomavirus oncoproteins: pathways to transformation,” 2010, https://doi.org/10.1038/nrc2886
[19]	H. Sung et al., “Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries,” CA Cancer J. Clin., vol. 76, no. 4, Jul. 2026, https://doi.org/10.3322/CAAC.70090
[20]	H. De Vuyst, F. Lillo, N. Broutet, and J. S. Smith, “HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy,” Nov. 2008. https://doi.org/10.1097/CEJ.0b013e3282f75ea1
[21]	T. D. Swase et al., “The impact of HPV/HIV co-infection on immunosuppression, HPV genotype, and cervical cancer biomarkers,” Dec. 01, 2025, BioMed Central Ltd. https://doi.org/10.1186/s12885-025-13516-2
[22]	D. Stelzle et al., “Articles Estimates of the global burden of cervical cancer associated with HIV,” Lancet Glob. Health, 2020, https://doi.org/10.1016/S2214-109X(20)30459-9
[23]	P. M. Day, R. Gambhira, R. B. S. Roden, D. R. Lowy, and J. T. Schiller, “Mechanisms of Human Papillomavirus Type 16 Neutralization by L2 Cross-Neutralizing and L1 Type-Specific Antibodies,” J. Virol., vol. 82, no. 9, pp. 4638–4646, May 2008, https://doi.org/10.1128/jvi.00143-08
[24]	J. T. Schiller and M. Müller, “Next generation prophylactic human papillomavirus vaccines,” Lancet Oncol., vol. 16, no. 5, pp. e217–e225, 2015, https://doi.org/10.1016/S1470-2045(14)71179-9
[25]	E. A. Joura et al., “A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women,” New England Journal of Medicine, vol. 372, no. 8, pp. 711–723, Feb. 2015, https://doi.org/10.1056/nejmoa1405044
[26]	M. Poljak, “Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: Issues and challenges,” 2012, Blackwell Publishing Ltd. https://doi.org/10.1111/j.1469-0691.2012.03946.x
[27]	A. L. Williamson, “Recent Developments in Human Papillomavirus (HPV) Vaccinology,” Jul. 01, 2023, Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/v15071440
[28]	J. T. Schiller and D. R. Lowy, “Understanding and learning from the success of prophylactic human papillomavirus vaccines,” Oct. 2012. https://doi.org/10.1038/nrmicro2872
[29]	J. T. Schiller, L. E. Markowitz, A. R. Kreimer, and D. R. Lowy, “Human Papilloma Virus Vaccine,” Plotkin’s Vaccines, Eighth Edition, pp. 484-513.e11, Feb. 2024, https://doi.org/10.1016/B978-0-323-79058-1.00032-3
[30]	L. A. Pinto, J. Dillner, S. Beddows, and E. R. Unger, “Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development,” Vaccine, vol. 36, no. 32, pp. 4792–4799, Aug. 2018, https://doi.org/10.1016/j.vaccine.2017.11.089
[31]	S. M. Garland et al., “Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases A BS T R AC T,” 2007. [Online]. Available: www.nejm.org
[32]	J. Paavonen, “Effi cacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women,” The Lancet, vol. 374, p. 301, 2009, https://doi.org/10.1016/S0140
[33]	M. Drolet et al., “Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis,” The Lancet, vol. 394, no. 10197, pp. 497–509, Aug. 2019, https://doi.org/10.1016/S0140-6736(19)30298-3
[34]	R. V. Barnabas et al., “Efficacy and durability of immediate versus delayed single-dose HPV vaccination for persistent infection among young women in Kenya: a randomized, blinded, cross-over clinical trial,” Nature Communications 2026 17:1, vol. 17, no. 1, pp. 6289-, May 2026, https://doi.org/10.1038/s41467-026-72654-8
[35]	R. V. Barnabas et al., “Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results,” Nat. Med., vol. 29, no. 12, pp. 3224–3232, Dec. 2023, https://doi.org/10.1038/S41591-023-02658-0
[36]	M. Falcaro et al., “The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study,” The Lancet, vol. 398, no. 10316, pp. 2084–2092, Dec. 2021, https://doi.org/10.1016/S0140-6736(21)02178-4
[37]	C. Patel et al., “The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: What additional disease burden will a nonavalent vaccine prevent?,” Oct. 11, 2018, European Centre for Disease Prevention and Control (ECDC). https://doi.org/10.2807/1560-7917.ES.2018.23.41.1700737
[38]	H. Ali et al., “Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data,” BMJ, vol. 346, no. 7907, May 2013, https://doi.org/10.1136/BMJ.F2032
[39]	J. M. Brotherton et al., “Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis,” Papillomavirus Res., vol. 8, Dec. 2019, https://doi.org/10.1016/J.PVR.2019.100177
[40]	M. T. Hall et al., “The projected timeframe until cervical cancer elimination in Australia: a modelling study,” Lancet Public Health, vol. 4, no. 1, pp. e19–e27, Jan. 2019, https://doi.org/10.1016/S2468-2667(18)30183-X
[41]	K. Kavanagh et al., “Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types,” Br. J. Cancer, vol. 110, no. 11, p. 2804, May 2014, https://doi.org/10.1038/BJC.2014.198
[42]	L. Bruni et al., “HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019,” Prev. Med. (Baltim)., vol. 144, p. 106399, Mar. 2021, https://doi.org/10.1016/J.YPMED.2020.106399
[43]	G. Murenzi and C. Mungo, “Impact of the human papillomavirus vaccine in low-resource settings,” Lancet Glob. Health, vol. 11, no. 7, p. e997, Jul. 2023, https://doi.org/10.1016/S2214-109X(23)00203-6
[44]	A. Binagwaho, C. M. Wagner, M. Gatera, C. Karema, C. T. Nutt, and F. Ngabo, “Atteinte d’un niveau de couverture élevé pour le programme national Rwandais de vaccination contre le papillomavirus humain,” Bull. World Health Organ., vol. 90, no. 8, pp. 623–628, Aug. 2012, https://doi.org/10.2471/BLT.11.097253
[45]	I. Baussano et al., “Impact of human papillomavirus vaccination, rwanda and Bhutan,” Emerg. Infect. Dis., vol. 27, no. 1, pp. 1–9, Jan. 2021, https://doi.org/10.3201/EID2701.191364
[46]	F. Sayinzoga, M. C. Umulisa, H. Sibomana, V. Tenet, I. Baussano, and G. M. Clifford, “Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort,” Vaccine, vol. 38, no. 24, p. 4001, May 2020, https://doi.org/10.1016/J.VACCINE.2020.04.021
[47]	C. Dochez et al., “Human Papillomavirus Vaccination in South Africa: Programmatic Challenges and Opportunities for Integration With Other Adolescent Health Services?,” Front. Public Health, vol. 10, p. 799984, Jan. 2022, https://doi.org/10.3389/FPUBH.2022.799984
[48]	K. E. Gallagher et al., “Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries,” PLoS One, vol. 12, no. 6, p. e0177773, Jun. 2017, https://doi.org/10.1371/JOURNAL.PONE.0177773
[49]	A. Tuli, M. Jit, K. Abbas, and A. Portnoy, “Projections of human papillomavirus (HPV) vaccination impact on non-cervical cancer outcomes among women in 117 low-income and middle-income countries: a modeling study,” medRxiv, p. 2025.06.24.25330224, Jun. 2025, https://doi.org/10.1101/2025.06.24.25330224
[50]	M. Drolet et al., “Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis,” Lancet Infect. Dis., vol. 21, no. 11, pp. 1598–1610, Nov. 2021, https://doi.org/10.1016/S1473-3099(20)30860-4
[51]	É. Bénard et al., “Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis,” Lancet Public Health, vol. 8, no. 10, pp. e788–e799, Oct. 2023, https://doi.org/10.1016/S2468-2667(23)00180-9
[52]	K. Canfell et al., “Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries,” The Lancet, vol. 395, no. 10224, pp. 591–603, Feb. 2020, https://doi.org/10.1016/S0140-6736(20)30157-4
[53]	M. Drolet et al., “Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis,” Lancet Infect. Dis., vol. 15, no. 5, pp. 565–580, May 2015, https://doi.org/10.1016/S1473-3099(14)71073-4
[54]	M. Brisson et al., “Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models,” Lancet Public Health, vol. 1, no. 1, pp. e8–e17, Nov. 2016, https://doi.org/10.1016/S2468-2667(16)30001-9
[55]	J. A. Bogaards, J. Wallinga, R. H. Brakenhoff, C. J. L. M. Meijer, and J. Berkhof, “Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: Bayesian evidence synthesis,” BMJ (Online), vol. 350, May 2015, https://doi.org/10.1136/BMJ.H2016
[56]	Q. Luo and Q. Ni, “Gender-neutral human papillomavirus vaccination: an equitable and cost-effective public health investment,” Front. Public Health, vol. 13, p. 1725127, Jan. 2026, https://doi.org/10.3389/FPUBH.2025.1725127/FULL
[57]	K. E. Gallagher et al., “Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007–2016,” Papillomavirus Research, vol. 4, pp. 72–78, Dec. 2017, https://doi.org/10.1016/J.PVR.2017.09.001
[58]	“Cervical Cancer Elimination Initiative.” Accessed: Jun. 30, 2026. [Online]. Available: https://www.who.int/initiatives/cervical-cancer-elimination-initiative
[59]	“Global strategy to accelerate the elimination of cervical cancer as a public health problem.” Accessed: Jul. 20, 2026. [Online]. Available: https://www.who.int/publications/i/item/9789240014107
[60]	WHO, “Kenya takes vital step against cervical cancer and introduces HPV vaccine into routine immunization \| WHO \| Regional Office for Africa.” Accessed: Jul. 20, 2026. [Online]. Available: https://www.afro.who.int/news/kenya-takes-vital-step-against-cervical-cancer-and-introduces-hpv-vaccine-routine-immunization
[61]	“KENYA NATIONAL IMMUNIZATION POLICY GUIDELINES”, Accessed: Jul. 20, 2026. [Online]. Available: http://www.health.go.ke
[62]	M. M. Masika, J. G. Ogembo, S. V. Chabeda, R. G. Wamai, and N. Mugo, “Knowledge on HPV Vaccine and Cervical Cancer Facilitates Vaccine Acceptability among School Teachers in Kitui County, Kenya,” PLoS One, vol. 10, no. 8, p. e0135563, Aug. 2015, https://doi.org/10.1371/JOURNAL.PONE.0135563
[63]	H. Vermandere, V. Naanyu, H. Mabeya, D. Vanden Broeck, K. Michielsen, and O. Degomme, “Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya,” PLoS One, vol. 9, no. 10, Oct. 2014, https://doi.org/10.1371/JOURNAL.PONE.0109353
[64]	GAVI, “Kenya introduces cervical cancer vaccine nationally.” Accessed: Jul. 20, 2026. [Online]. Available: https://www.gavi.org/news/media-room/kenya-introduces-cervical-cancer-vaccine-nationally
[65]	“Weekly epidemiological record Relevé épidémiologique hebdomadaire Sommaire.” [Online]. Available: https://www.hpvcenter.se/human_reference_clones/
[66]	WHO, “WHO updates recommendations on HPV vaccination schedule.” Accessed: Jul. 20, 2026. [Online]. Available: https://www.who.int/news/item/20-12-2022-WHO-updates-recommendations-on-HPV-vaccination-schedule
[67]	“Immunization coverage.” Accessed: Jun. 30, 2026. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/immunization-coverage
[68]	“Human Papillomavirus (HPV) vaccination coverage.” Accessed: Sep. 21, 2026. [Online]. Available: https://immunizationdata.who.int/global/wiise-detail-page/human-papillomavirus-(hpv)-vaccination-coverage
[69]	A. L. Friedman et al., “Preparing for human papillomavirus vaccine introduction in Kenya: implications from focus-group and interview discussions with caregivers and opinion leaders in Western Kenya,” BMC Public Health, vol. 14, no. 1, p. 855, 2014, https://doi.org/10.1186/1471-2458-14-855
[70]	C. M. Karanja-Chege, “HPV Vaccination in Kenya: The Challenges Faced and Strategies to Increase Uptake,” Mar. 21, 2022, Frontiers Media S.A. https://doi.org/10.3389/fpubh.2022.802947
[71]	“Global childhood immunization coverage inches forward despite conflict and hesitancy – UNICEF, WHO.” Accessed: Jul. 22, 2026. [Online]. Available: https://www.unicef.org/kenya/press-releases/global%E2%80%AFchildhood-immunization%E2%80%AFcoverage-inches-forward%E2%80%AFdespite-conflict-and%E2%80%AFhesitancy
[72]	M. Jit, M. Brisson, A. Portnoy, and R. Hutubessy, “Cost-effectiveness of female human papillomavirus vaccination in 179 countries: A PRIME modelling study,” Lancet Glob. Health, vol. 2, no. 7, pp. e406–e414, 2014, https://doi.org/10.1016/S2214-109X(14)70237-2
[73]	R. V. Barnabas et al., “Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women,” NEJM Evidence, vol. 1, no. 5, Apr. 2022, https://doi.org/10.1056/evidoa2100056
[74]	R. J. Limaye et al., “Understanding Kenyan policymakers’ perspectives about the introduction of new maternal vaccines,” Health Policy Plan., vol. 40, no. 1, p. 23, Jan. 2024, https://doi.org/10.1093/HEAPOL/CZAE059
[75]	J. O. Ogolla, D. R. Masinde, and A. M. Mbeke, “Factors associated with human papilloma virus vaccine uptake before the health awareness, learning and education intervention in Korogocho Informal Settlements in Nairobi County, Kenya,” Ecancermedicalscience, vol. 19, 2025, https://doi.org/10.3332/ecancer.2025.1892
[76]	L. L. Black, G. D. Zimet, M. B. Short, L. Sturm, and S. L. Rosenthal, “Literature review of human papillomavirus vaccine acceptability among women over 26 years,” Mar. 10, 2009. https://doi.org/10.1016/j.vaccine.2009.01.035
[77]	N. S. Salleh, K. L. Abdullah, and H. Y. Chow, “Cultural barriers and facilitators of the parents for human papillomavirus (HPV) vaccination uptake by their daughters: A systematic review,” Mar. 01, 2025, Elsevier Editora Ltda. https://doi.org/10.1016/j.jped.2024.07.012
[78]	V. Snijders et al., “An approach to capturing the cultural contexts of health behaviours,” Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, vol. 68, no. 9, p. 978, Sep. 2025, https://doi.org/10.1007/S00103-025-04105-6
[79]	E. O. Ochomo et al., “‘Addressing HPV vaccine hesitancy: unveiling concerns and building trust’ perspectives of adolescent girls and parents in Kisumu County, Kenya,” Ecancermedicalscience, vol. 18, 2024, https://doi.org/10.3332/ECANCER.2024.1735
[80]	K. Unfried and J. Priebe, “Who shares fake news on social media? Evidence from vaccines and infertility claims in sub-Saharan Africa,” PLoS One, vol. 19, no. 4, p. e0301818, Apr. 2024, https://doi.org/10.1371/JOURNAL.PONE.0301818
[81]	Interpeace, “A Comprehensive Study of Health Gaps and Needs in the Mandera Triangle The Cross-Border Health for Peace Programme.” [Online]. Available: www.interpeace.org
[82]	“‘Afya Yetu, Jukumu Letu.’” [Online]. Available: https://www.health.go.ke/
[83]	D. K. Sinnei, P. N. Karimi, S. M. Maru, S. Karengera, and T. Bizimana, “Evaluation of vaccine storage and distribution practices in rural healthcare facilities in Kenya,” J. Pharm. Policy Pract., vol. 16, no. 1, p. 25, Dec. 2023, https://doi.org/10.1186/S40545-023-00535-2
[84]	S. Allan, I. M. O. Adetifa, and K. Abbas, “Inequities in childhood immunisation coverage associated with socioeconomic, geographic, maternal, child, and place of birth characteristics in Kenya,” BMC Infect. Dis., vol. 21, no. 1, p. 553, Dec. 2021, https://doi.org/10.1186/S12879-021-06271-9
[85]	C. S. Shumba, P. Kiraithe, I. Kambo, and S. Shaibu, “Community Health Volunteers’ experiences of implementing COVID-19 vaccine education and promotion in Kenya: a qualitative descriptive study,” Front. Public Health, vol. 12, 2024, https://doi.org/10.3389/fpubh.2024.1406959
[86]	N. Kagwanja et al., “Understanding what factors influence community health worker involvement in hypertension service delivery in Kenya: applying a community health system lens Key messages,” Health Policy Plan., vol. 2026, no. 4, pp. 627–639, 2026, https://doi.org/10.1093/heapol/czag020
[87]	N. K. Joseph et al., “Spatial access inequities and childhood immunisation uptake in Kenya,” BMC Public Health, vol. 20, no. 1, p. 1407, Sep. 2020, https://doi.org/10.1186/S12889-020-09486-8
[88]	“Closing the HPV Vaccination Gap: 4 Strategies to Reach Out-Of-School Girls - JSI Research & Training Institute, Inc.” Accessed: May 25, 2026. [Online]. Available: https://www.jsi.org/closing-hpv-vaccination-gap-4-strategies/
[89]	R. B. Khatri et al., “Enablers and barriers of community health programs for improved equity and universal coverage of primary health care services: A scoping review,” BMC Primary Care, vol. 25, no. 1, p. 385, Dec. 2024, https://doi.org/10.1186/S12875-024-02629-5
[90]	E. and M. H. and M. D. B. on H. C. S. D. of B. and S. S. and E. B. on C. Y. and F. C. on I. the H. and W. of C. and Y. National Academies of Sciences, J. M. Perrin, and T. L. Cheng, “Opportunities for Health Promotion and Disease Prevention in Schools,” Launching Lifelong Health by Improving Health Care for Children, Youth, and Families, pp. 1–570, Dec. 2024, https://doi.org/10.17226/27835
[91]	C. Nunes, M. McKee, and N. Howard, “The role of global health partnerships in vaccine equity: A scoping review,” PLOS Global Public Health, vol. 4, no. 2, p. e0002834, Feb. 2024, https://doi.org/10.1371/JOURNAL.PGPH.0002834
[92]	“Strong progress in lower-income countries underscores need for sustained investment in immunisation.” Accessed: Jul. 22, 2026. [Online]. Available: https://www.gavi.org/news/media-room/strong-progress-lower-income-countries-underscores-need-sustained-investment
[93]	O. S. Ilesanmi and A. A. Afolabi, “Sustainability of Donor-Funded Health-Related Programs Beyond the Funding Lifecycle in Africa: A Systematic Review,” Cureus, vol. 14, no. 5, p. e24643, May 2022, https://doi.org/10.7759/CUREUS.24643
[94]	J. B. Bangura, S. Xiao, D. Qiu, F. Ouyang, and L. Chen, “Barriers to childhood immunization in sub-Saharan Africa: A systematic review,” Jul. 14, 2020, BioMed Central. https://doi.org/10.1186/s12889-020-09169-4
[95]	G. Umutesi et al., “HPV vaccination in Kenya: a study protocol to assess stakeholders’ perspectives on implementation drivers of HPV vaccination and the acceptability of the reduced dose strategy among providers,” Frontiers in Health Services, vol. 3, 2023, https://doi.org/10.3389/frhs.2023.1233923
[96]	V. D. Tsu, D. S. LaMontagne, P. Atuhebwe, P. N. Bloem, and C. Ndiaye, “National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects,” Prev. Med. (Baltim)., vol. 144, Mar. 2021, https://doi.org/10.1016/j.ypmed.2020.106335
[97]	T. N. Maseko, X. Dlamini, V. Okello, R. Nkambule, J. M. Tsoka-Gwegweni, and J. P. M. Milambo, “Introduction of the HPV Vaccine among Young Girls to Reduce the Long-Term Risk of Cervical Cancer in Eswatini: Programmatic Decision and Roll Out,” Jun. 01, 2025, Asian Pacific Organization for Cancer Prevention. https://doi.org/10.31557/APJCP.2025.26.6.1891
[98]	I. Man, D. Georges, P. Basu, and I. Baussano, “Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings,” J. Natl. Cancer Inst. Monogr., vol. 2024, no. 67, pp. 400–409, 2024, https://doi.org/10.1093/jncimonographs/lgae035
[99]	D. Engel et al., “Promoting adolescent health through integrated human papillomavirus vaccination programs: The experience of Togo,” Vaccine, vol. 40, pp. A100–A106, Mar. 2022, https://doi.org/10.1016/J.VACCINE.2021.11.021
[100]	C. Morgan et al., “Integration of other services with human papillomavirus vaccination; lessons from earlier in the life course highlight the need for new policy and implementation evidence,” Vaccine, vol. 40, pp. A94–A99, Mar. 2022, https://doi.org/10.1016/J.VACCINE.2021.12.066
[101]	N. M. Wagner et al., “Addressing logistical barriers to childhood vaccination using an automated reminder system and online resource intervention: A randomized controlled trial,” Vaccine, vol. 39, no. 29, pp. 3983–3990, Jun. 2021, https://doi.org/10.1016/j.vaccine.2021.05.053
[102]	A. Braga et al., “Global Perspectives on HPV Vaccination: Achievements, Challenges, and Lessons from the Brazilian Experience,” Nov. 01, 2025, Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/vaccines13111106
[103]	J. Lin, S. M. Bates, L. N. Allen, M. Wright, L. Mao, and M. Kidd, “Integrating Mobile Health App Data Into Electronic Medical or Health Record Systems and Its Impact on Health Care Delivery and Patient Health Outcomes: Scoping Review,” JMIR Mhealth Uhealth, vol. 13, p. e66650, 2025, https://doi.org/10.2196/66650
[104]	R. L. Valdecantos et al., “The structural and organizational aspects of human papillomavirus vaccine affecting immunization coverage in Europe: a systematic review,” Dec. 01, 2025, BioMed Central Ltd. https://doi.org/10.1186/s12889-025-22343-w
[105]	S. K. Kjaer, C. Dehlendorff, F. Belmonte, and L. Baandrup, “Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer,” JNCI Journal of the National Cancer Institute, vol. 113, no. 10, p. 1329, Oct. 2021, https://doi.org/10.1093/JNCI/DJAB080
[106]	E. Tortellini et al., “Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus,” Viruses, vol. 15, no. 9, p. 1844, Sep. 2023, https://doi.org/10.3390/V15091844
[107]	E. A. Burger et al., “Single-dose HPV vaccination in the United States — a multi-modeling analysis,” Lancet Regional Health - Americas, vol. 55, p. 101361, Mar. 2026, https://doi.org/10.1016/J.LANA.2025.101361
[108]	J. K. Njue, M. W. Muturi, L. M. K. and R. Lwembe, J. K. Njue, M. W. Muturi, and L. M. K. and R. Lwembe, “Closing the Cervical Cancer Gap: Integrating HPV Genotyping, Cervical Dysplasia Screening, Vaccination, and Community Awareness in Eastern Kenya,” Aug. 2026, https://doi.org/10.5772/INTECHOPEN.1012871
[109]	L. Li, C. E. Wood, and P. Kostkova, “Vaccine hesitancy and behavior change theory-based social media interventions: a systematic review,” Transl. Behav. Med., vol. 12, no. 2, p. 243, Feb. 2021, https://doi.org/10.1093/TBM/IBAB148

Cite This Article

Plain Text BibTeX RIS

APA Style

Adams, M. K., Walter, L., Katuah, Z., Esther, N., Ogot, A., et al. (2026). Human Papillomavirus (HPV) Vaccination and the Impact of Vaccine Implementation in Kenya: Progress, Challenges, and Future Directions. Frontiers, 6(3), 107-120. https://doi.org/10.11648/j.frontiers.20260603.14

Copy | Download

ACS Style

Adams, M. K.; Walter, L.; Katuah, Z.; Esther, N.; Ogot, A., et al. Human Papillomavirus (HPV) Vaccination and the Impact of Vaccine Implementation in Kenya: Progress, Challenges, and Future Directions. Frontiers. 2026, 6(3), 107-120. doi: 10.11648/j.frontiers.20260603.14

Copy | Download

AMA Style

Adams MK, Walter L, Katuah Z, Esther N, Ogot A, et al. Human Papillomavirus (HPV) Vaccination and the Impact of Vaccine Implementation in Kenya: Progress, Challenges, and Future Directions. Frontiers. 2026;6(3):107-120. doi: 10.11648/j.frontiers.20260603.14

Copy | Download

@article{10.11648/j.frontiers.20260603.14,
  author = {Maru Kiplimo Adams and Lelei Walter and Zefaniah Katuah and Njagi Esther and Amy Ogot and Rispah Torrorey and Simeon Mining},
  title = {Human Papillomavirus (HPV) Vaccination and the Impact of Vaccine Implementation in Kenya: Progress, Challenges, and Future Directions},
  journal = {Frontiers},
  volume = {6},
  number = {3},
  pages = {107-120},
  doi = {10.11648/j.frontiers.20260603.14},
  url = {https://doi.org/10.11648/j.frontiers.20260603.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.frontiers.20260603.14},
  abstract = {Human papillomavirus (HPV) is the primary etiological agent of cervical cancer, a disease that remains a major cause of cancer-related morbidity and mortality among women in Kenya despite the availability of highly effective prophylactic vaccines. This review examines the current evidence on HPV virology, vaccine immunology, global vaccine effectiveness, and the implementation of HPV vaccination in Kenya following its introduction into the national immunization program in 2019. It also evaluates progress in vaccine delivery, coverage trends, and the adoption of the single-dose vaccination schedule, while highlighting persistent challenges including vaccine hesitancy, inequitable access, health system constraints, and socioeconomic barriers. Available evidence indicates that HPV vaccination has strengthened cervical cancer prevention efforts and has the potential to substantially reduce the future burden of HPV-related disease. However, vaccine coverage remains below the World Health Organization target for cervical cancer elimination, limiting the full public health impact of the program. Key research priorities include evaluating long-term vaccine effectiveness, monitoring HPV genotype dynamics, assessing vaccine performance among people living with HIV, and strengthening the integration of HPV vaccination with cervical cancer screening programs. Achieving equitable vaccine access, enhancing surveillance systems, improving community engagement, and ensuring sustainable financing will be essential to maximizing the benefits of HPV vaccination and accelerating progress toward the elimination of cervical cancer in Kenya.},
 year = {2026}
}

Copy | Download

TY  - JOUR
T1  - Human Papillomavirus (HPV) Vaccination and the Impact of Vaccine Implementation in Kenya: Progress, Challenges, and Future Directions
AU  - Maru Kiplimo Adams
AU  - Lelei Walter
AU  - Zefaniah Katuah
AU  - Njagi Esther
AU  - Amy Ogot
AU  - Rispah Torrorey
AU  - Simeon Mining
Y1  - 2026/09/29
PY  - 2026
N1  - https://doi.org/10.11648/j.frontiers.20260603.14
DO  - 10.11648/j.frontiers.20260603.14
T2  - Frontiers
JF  - Frontiers
JO  - Frontiers
SP  - 107
EP  - 120
PB  - Science Publishing Group
SN  - 2994-7197
UR  - https://doi.org/10.11648/j.frontiers.20260603.14
AB  - Human papillomavirus (HPV) is the primary etiological agent of cervical cancer, a disease that remains a major cause of cancer-related morbidity and mortality among women in Kenya despite the availability of highly effective prophylactic vaccines. This review examines the current evidence on HPV virology, vaccine immunology, global vaccine effectiveness, and the implementation of HPV vaccination in Kenya following its introduction into the national immunization program in 2019. It also evaluates progress in vaccine delivery, coverage trends, and the adoption of the single-dose vaccination schedule, while highlighting persistent challenges including vaccine hesitancy, inequitable access, health system constraints, and socioeconomic barriers. Available evidence indicates that HPV vaccination has strengthened cervical cancer prevention efforts and has the potential to substantially reduce the future burden of HPV-related disease. However, vaccine coverage remains below the World Health Organization target for cervical cancer elimination, limiting the full public health impact of the program. Key research priorities include evaluating long-term vaccine effectiveness, monitoring HPV genotype dynamics, assessing vaccine performance among people living with HIV, and strengthening the integration of HPV vaccination with cervical cancer screening programs. Achieving equitable vaccine access, enhancing surveillance systems, improving community engagement, and ensuring sustainable financing will be essential to maximizing the benefits of HPV vaccination and accelerating progress toward the elimination of cervical cancer in Kenya.
VL  - 6
IS  - 3
ER  -

Copy | Download

Author Information

Maru Kiplimo Adams

Department of Pathology, Moi University, Eldoret, Kenya;Department of Medical Laboratory Sciences, University of Eastern Africa, Baraton, Kenya

Contact Email

http://orcid.org/0009-0005-6831-8626
Lelei Walter

Department of Medical Laboratory Sciences, University of Eastern Africa, Baraton, Kenya

http://orcid.org/0009-0005-9699-2511
Zefaniah Katuah

Department of Biomedical Sciences, Kamuzu University of Health Sciences, Zomba, Malawi
Njagi Esther

Department of Medical Laboratory Sciences, University of Eastern Africa, Baraton, Kenya

http://orcid.org/0000-0002-8075-7542
Amy Ogot

Department of Medical Laboratory Sciences, University of Eastern Africa, Baraton, Kenya
Rispah Torrorey

Department of Pathology, Moi University, Eldoret, Kenya
Simeon Mining

Department of Pathology, Moi University, Eldoret, Kenya

Download PDF

Submit an Article

Sections

Plain Text BibTeX RIS

APA Style

Adams, M. K., Walter, L., Katuah, Z., Esther, N., Ogot, A., et al. (2026). Human Papillomavirus (HPV) Vaccination and the Impact of Vaccine Implementation in Kenya: Progress, Challenges, and Future Directions. Frontiers, 6(3), 107-120. https://doi.org/10.11648/j.frontiers.20260603.14

Copy | Download

ACS Style

Adams, M. K.; Walter, L.; Katuah, Z.; Esther, N.; Ogot, A., et al. Human Papillomavirus (HPV) Vaccination and the Impact of Vaccine Implementation in Kenya: Progress, Challenges, and Future Directions. Frontiers. 2026, 6(3), 107-120. doi: 10.11648/j.frontiers.20260603.14

Copy | Download

AMA Style

Adams MK, Walter L, Katuah Z, Esther N, Ogot A, et al. Human Papillomavirus (HPV) Vaccination and the Impact of Vaccine Implementation in Kenya: Progress, Challenges, and Future Directions. Frontiers. 2026;6(3):107-120. doi: 10.11648/j.frontiers.20260603.14

Copy | Download

@article{10.11648/j.frontiers.20260603.14,
  author = {Maru Kiplimo Adams and Lelei Walter and Zefaniah Katuah and Njagi Esther and Amy Ogot and Rispah Torrorey and Simeon Mining},
  title = {Human Papillomavirus (HPV) Vaccination and the Impact of Vaccine Implementation in Kenya: Progress, Challenges, and Future Directions},
  journal = {Frontiers},
  volume = {6},
  number = {3},
  pages = {107-120},
  doi = {10.11648/j.frontiers.20260603.14},
  url = {https://doi.org/10.11648/j.frontiers.20260603.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.frontiers.20260603.14},
  abstract = {Human papillomavirus (HPV) is the primary etiological agent of cervical cancer, a disease that remains a major cause of cancer-related morbidity and mortality among women in Kenya despite the availability of highly effective prophylactic vaccines. This review examines the current evidence on HPV virology, vaccine immunology, global vaccine effectiveness, and the implementation of HPV vaccination in Kenya following its introduction into the national immunization program in 2019. It also evaluates progress in vaccine delivery, coverage trends, and the adoption of the single-dose vaccination schedule, while highlighting persistent challenges including vaccine hesitancy, inequitable access, health system constraints, and socioeconomic barriers. Available evidence indicates that HPV vaccination has strengthened cervical cancer prevention efforts and has the potential to substantially reduce the future burden of HPV-related disease. However, vaccine coverage remains below the World Health Organization target for cervical cancer elimination, limiting the full public health impact of the program. Key research priorities include evaluating long-term vaccine effectiveness, monitoring HPV genotype dynamics, assessing vaccine performance among people living with HIV, and strengthening the integration of HPV vaccination with cervical cancer screening programs. Achieving equitable vaccine access, enhancing surveillance systems, improving community engagement, and ensuring sustainable financing will be essential to maximizing the benefits of HPV vaccination and accelerating progress toward the elimination of cervical cancer in Kenya.},
 year = {2026}
}

Copy | Download

TY  - JOUR
T1  - Human Papillomavirus (HPV) Vaccination and the Impact of Vaccine Implementation in Kenya: Progress, Challenges, and Future Directions
AU  - Maru Kiplimo Adams
AU  - Lelei Walter
AU  - Zefaniah Katuah
AU  - Njagi Esther
AU  - Amy Ogot
AU  - Rispah Torrorey
AU  - Simeon Mining
Y1  - 2026/09/29
PY  - 2026
N1  - https://doi.org/10.11648/j.frontiers.20260603.14
DO  - 10.11648/j.frontiers.20260603.14
T2  - Frontiers
JF  - Frontiers
JO  - Frontiers
SP  - 107
EP  - 120
PB  - Science Publishing Group
SN  - 2994-7197
UR  - https://doi.org/10.11648/j.frontiers.20260603.14
AB  - Human papillomavirus (HPV) is the primary etiological agent of cervical cancer, a disease that remains a major cause of cancer-related morbidity and mortality among women in Kenya despite the availability of highly effective prophylactic vaccines. This review examines the current evidence on HPV virology, vaccine immunology, global vaccine effectiveness, and the implementation of HPV vaccination in Kenya following its introduction into the national immunization program in 2019. It also evaluates progress in vaccine delivery, coverage trends, and the adoption of the single-dose vaccination schedule, while highlighting persistent challenges including vaccine hesitancy, inequitable access, health system constraints, and socioeconomic barriers. Available evidence indicates that HPV vaccination has strengthened cervical cancer prevention efforts and has the potential to substantially reduce the future burden of HPV-related disease. However, vaccine coverage remains below the World Health Organization target for cervical cancer elimination, limiting the full public health impact of the program. Key research priorities include evaluating long-term vaccine effectiveness, monitoring HPV genotype dynamics, assessing vaccine performance among people living with HIV, and strengthening the integration of HPV vaccination with cervical cancer screening programs. Achieving equitable vaccine access, enhancing surveillance systems, improving community engagement, and ensuring sustainable financing will be essential to maximizing the benefits of HPV vaccination and accelerating progress toward the elimination of cervical cancer in Kenya.
VL  - 6
IS  - 3
ER  -

Copy | Download